127 related articles for article (PubMed ID: 3490935)
1. Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.
Miyasaka N; Murota N; Yamaoka K; Sato K; Yamada T; Nishido T; Okuda M
Clin Exp Immunol; 1986 Sep; 65(3):497-505. PubMed ID: 3490935
[TBL] [Abstract][Full Text] [Related]
2. Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjögren's syndrome.
Gerli R; Bertotto A; Agea E; Lanfrancone L; Cernetti C; Spinozzi F; Rambotti P
J Clin Invest; 1990 Dec; 86(6):1870-7. PubMed ID: 1979333
[TBL] [Abstract][Full Text] [Related]
3. Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjögren's syndrome. Detection of reactive cells by using antibody directed to synthetic peptides of IL 2.
Fox RI; Theofilopoulos AN; Altman A
J Immunol; 1985 Nov; 135(5):3109-15. PubMed ID: 3876375
[TBL] [Abstract][Full Text] [Related]
4. Biochemical deficiency of pyridoxine does not affect interleukin-2 production of lymphocytes from patients with Sjögren's syndrome.
Tovar AR; Gómez E; Bourges H; Ortíz V; Kraus A; Torres N
Eur J Clin Nutr; 2002 Nov; 56(11):1087-93. PubMed ID: 12428174
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo CD(+) T-cell cytokine expression from patients with Sjögren's syndrome following in vitro stimulation to induce proliferation.
Koarada S; Haruta Y; Mitamura M; Morito F; Tada Y; Ohta A; Nagasawa K
Rheumatology (Oxford); 2006 Apr; 45(4):392-9. PubMed ID: 16287915
[TBL] [Abstract][Full Text] [Related]
6. Blood mononuclear cells in patients with primary Sjögren's syndrome: production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis.
Enk C; Oxholm P; Tvede N; Bendtzen K
Scand J Rheumatol Suppl; 1986; 61():131-4. PubMed ID: 3109021
[TBL] [Abstract][Full Text] [Related]
7. Sjögren's syndrome with myalgia is associated with subnormal secretion of cytokines by peripheral blood mononuclear cells.
Eriksson P; Andersson C; Ekerfelt C; Ernerudh J; Skogh T
J Rheumatol; 2004 Apr; 31(4):729-35. PubMed ID: 15088299
[TBL] [Abstract][Full Text] [Related]
8. IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
Shen L; Suresh L; Li H; Zhang C; Kumar V; Pankewycz O; Ambrus JL
Clin Immunol; 2009 Mar; 130(3):304-12. PubMed ID: 19038581
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.
Pedersen BK; Oxholm P; Manthorpe R; Andersen V
Clin Exp Immunol; 1986 Jan; 63(1):1-7. PubMed ID: 3485480
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulation in Sjögren's syndrome: influence of serum factors on T-cell subpopulations.
Moutsopoulos HM; Fauci AS
J Clin Invest; 1980 Feb; 65(2):519-28. PubMed ID: 6444308
[TBL] [Abstract][Full Text] [Related]
11. Production of interleukin 2 in multiple myeloma.
Commes T; Klein B; Jourdan M; Bataille R
Clin Exp Immunol; 1986 Mar; 63(3):533-40. PubMed ID: 3486731
[TBL] [Abstract][Full Text] [Related]
12. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.
Manoussakis MN; Boiu S; Korkolopoulou P; Kapsogeorgou EK; Kavantzas N; Ziakas P; Patsouris E; Moutsopoulos HM
Arthritis Rheum; 2007 Dec; 56(12):3977-88. PubMed ID: 18050195
[TBL] [Abstract][Full Text] [Related]
13. An analysis of polyclonal B cell activation in Sjögren's syndrome. Characterization of B cell lines spontaneously established from the peripheral blood.
Miyasaka N; Yamaoka K; Sato K; Kubota T; Okuda M; Nishioka K; Ohya Y; Yamamoto K
Scand J Rheumatol Suppl; 1986; 61():123-6. PubMed ID: 3495872
[TBL] [Abstract][Full Text] [Related]
14. Activation antigens in patients with Sjögren's syndrome.
Zeher M; Pálóczi K; Szegedi G
Haematologia (Budap); 1990; 23(4):193-7. PubMed ID: 2101803
[TBL] [Abstract][Full Text] [Related]
15. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome.
van Woerkom JM; Kruize AA; Wenting-van Wijk MJ; Knol E; Bihari IC; Jacobs JW; Bijlsma JW; Lafeber FP; van Roon JA
Ann Rheum Dis; 2005 Oct; 64(10):1474-9. PubMed ID: 15817659
[TBL] [Abstract][Full Text] [Related]
16. [Cell-mediated immunity in patients with Sjogren's syndrome].
Krejsek J; Slezák R; Kopecký O; Vokurková D; Loudová M; Derner V
Cas Lek Cesk; 1997 Jan; 136(2):44-7. PubMed ID: 9147852
[TBL] [Abstract][Full Text] [Related]
17. Impaired indomethacin-boosting of the defective natural killer cell activity in patients with primary Sjögren's syndrome.
Pedersen BK; Oxholm P; Manthorpe R; Andersen V
Scand J Rheumatol Suppl; 1986; 61():135-8. PubMed ID: 3473621
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin.
Murray JL; Dowd J; Hersh EM
J Biol Response Mod; 1986 Feb; 5(1):12-9. PubMed ID: 3485703
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and functional abnormalities in the peripheral blood T-cells of patients with primary Sjogren's syndrome.
Aziz KE; McCluskey PJ; Wakefield D
Cytometry; 1994 Mar; 18(1):35-41. PubMed ID: 8082485
[TBL] [Abstract][Full Text] [Related]
20. [Decreased IL-2 production in Sjögren's syndrome].
Miyasaka N; Yamada T; Sato K; Murata H; Yada J; Nishida T; Okuda M
Ryumachi; 1984 Jun; 24(3):166-72. PubMed ID: 6334371
[No Abstract] [Full Text] [Related]
[Next] [New Search]
